AstraZeneca
AZN
982 hedge funds and large institutions have $34.3B invested in AstraZeneca in 2022 Q1 according to their latest regulatory filings, with 121 funds opening new positions, 338 increasing their positions, 301 reducing their positions, and 79 closing their positions.
53% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 79
31% more funds holding in top 10
Funds holding in top 10: 13 → 17 (+4)
17% more capital invested
Capital invested by funds: $29.4B → $34.3B (+$4.87B)
12% more repeat investments, than reductions
Existing positions increased: 338 | Existing positions reduced: 301
3% more funds holding
Funds holding: 949 → 982 (+33)
10% more call options, than puts
Call options by funds: $495M | Put options by funds: $450M
0.38% more ownership
Funds ownership: 16.29% → 16.67% (+0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$317M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$263M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$197M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$149M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$128M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$414M |
| 2 |
Janus Henderson Group
London,
|
-$150M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$81.8M |
| 4 |
Renaissance Technologies
New York
|
-$75.4M |
| 5 |
Legal & General Group
London,
United Kingdom
|
-$73.3M |
AZN Hedge Fund Activity: Q1 2022 in Review
982 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2022, worth a combined $34.3B — up 17% from $29.4B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new AZN positions and 79 closed out — a net gain of 42 holders — while 338 added to existing stakes and 301 trimmed.
The largest buyer was Franklin Resources, adding an estimated $317M. The largest seller was HSBC Holdings, cutting an estimated $414M.
- 982 institutional investors held AstraZeneca (AZN) as of Q1 2022, up from 949 in Q4 2021.
- Funds reported $34.3B of AstraZeneca stock for Q1 2022, up 17% quarter-over-quarter.
- 121 funds opened new AstraZeneca positions in Q1 2022 and 79 closed out, a net change of +42 holders.
- The largest AstraZeneca buyer in Q1 2022 was Franklin Resources, an estimated $317M added.
- The largest AstraZeneca seller in Q1 2022 was HSBC Holdings, an estimated $414M sold.
Based on aggregated 13F filings for Q1 2022.